세계의 맞춤형 암 백신 시장 규모, 점유율, 동향 분석 보고서 : 유형별, 기술별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Personalized Cancer Vaccine Market Size, Share & Trends Analysis Report By Type (Dendritic Cell, RNA-based (mRNA), Neoantigen-based), By Technology (Cell-based, mRNA PCV), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,158,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,529,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,271,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

세계의 맞춤형 암 백신 시장의 성장과 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 맞춤형 암 백신 시장 규모는 2025-2030년까지 44.86%의 연평균 복합 성장률(CAGR)을 기록하며, 2030년 14억 5,000만 달러에 달할 것으로 예측되고 있습니다.

면역요법, 유전체학, mRNA 기술의 융합이 시장 성장의 원동력이 되고 있습니다. 이 높은 정확도는 특히 치료가 어려운 암을 대상으로 종양학에 새로운 치료의 지평을 열었습니다. 시장의 성장은 바이오테크놀러지에 투자 증가, 세계의 암 이환율 증가, 차세대 시퀀서의 진보에 의해 추진되고 있습니다. 이 백신은 더 이상 투기적인 치료가 아니고, 장래의 종양학의 전망에 불가결한 것이 되고 있습니다.

시장 성장의 가장 중요한 촉진요인 중 하나는 mRNA 기반 백신 플랫폼의 혁신입니다. mRNA 백신의 성공은 이 치료법에 대한 관민 섹터의 신뢰를 가속화하고 자금 조달 증가와 규제 당국에의 신속한 대응으로 이어졌습니다. 2023년 4월에 EMA로부터 PRIME 지정을 받은 이 백신은 2b상 임상 검사(KEYNOTE-942)에서 유망한 결과를 나타내고 특히 Merck의 면역요법약 KEYTRUDA와 조합했을 경우에 현저했습니다. 마찬가지로, mRNA 기술의 선구자인 BioNTech은 2024년 4월에 개최된 AACR 연차 총회에서 mRNA 베이스의 암 백신과 항체 약제 복합체를 중심으로, 암 영역의 파이프라인을 전시했습니다. 기술 혁신에 의해 연구자는 종양의 염기서열에 기초하여 백신 후보를 신속하게 생성하고 거의 실시간으로 치료를 맞춤형하고 면역반응을 미세조정하여 효능을 높일 수 있게 되어 암치료의 신시대에의 길이 열리고 있습니다.

HPV 감염, 관련 건강 위험, 예방 접종의 이점에 대한 세계 의식 증가는 시장 성장을 가속하는 주요 요인입니다. 호주나 영국 등, 헬스케어 커뮤니케이션 전략이 확실히 하고 있는 국가에서는 HPV 백신의 접종율이 두드러지게 높아, 이것은 일관된 근거에 의한 계발 활동의 효과를 반영하고 있습니다. 따로 잡히지 않는 백신 접종의 메시징은 특히 남성에 있어서의 중인두암이나 항문암의 이환율 증가를 받아, 남성 집단의 수용도 개선하고 있습니다.

맞춤형된 암 백신 산업을 가속화하는 데 있어 규제 인센티브가 중요한 역할을 하고 있습니다. Moderna와 Merck의 mRNA-4157/V940 백신이 PRIME에 지정된 것은 암 영역에서의 혁신을 촉진하는 규제 당국의 헌신의 증거입니다. 이 지정은 고리스크의 스테이지 3 및 4의 환자가 KEYTRUDA와 병행하여 백신을 투여하면 수술 후 결과가 개선되었음을 시사하는 긍정적인 중간 데이터를 기반으로 합니다.

맞춤형 암 백신 시장 보고서 하이라이트

• 유형별로는 수상세포 부문이 2024년에 100%의 최대 시장 점유율을 차지해, 표적 면역요법과 맞춤형 면역요법 수요 증가에 견인되었습니다.
• 세포기반기술부문은 표적화 및 적응화 항종양 반응을 위해 체내의 면역계를 이용하는 능력에 지지되어 2024년의 수익 점유율 100%로 시장을 리드했습니다.
• 병원 부문은 2024년 수익 점유율 58.87%에서 시장을 독점하고, 몇 가지 중요한 요인에 의해 예측 기간 동안 가장 빠른 CAGR로 성장할 것으로 예상되고 있습니다.
• 북미는 면역요법의 진전과 강력한 헬스케어 인프라가 견인해 2024년에는 34.07%의 점유율을 획득하여 세계 시장을 석권했습니다.
• 세계의 맞춤형 백신 산업은 Dendreon Pharmaceuticals, LLC, Gritstone Bio, CureVac, NeoCura & Innovent, Stemirna Therapeutics, Dendreon Pharmaceuticals, LLC, Elicio Therapeutics, Evaxion BIoTech, Imugene, Nouscom 등 주요 기업이 견인하고 있으며, 이들 기업은 신제품 상시, 전략적 파트너십 체결, 새로운 지역 진출 등의 전략을 통해 세계적인 존재를 강화하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 맞춤형 암 백신 시장의 변수, 동향, 범위

• 시장 세분화 및 범위
• 시장 계통의 전망
  • 모 시장 전망
  • 관련/보조시장 전망
• 시장 동향과 전망
• 시장 역학
  • 유전체과 면역요법 기술의 진보
  • 암 이환율의 상승과 표적 치료 수요
  • 암 면역요법에서의 협력과 투자 증가
• 시장 성장 억제요인 분석
  • 높은 개발 및 제조 비용
  • 규제와 물류상의 과제
  • Porter's Five Forces 분석
  • PESTEL 분석

제4장 맞춤형암 백신 시장 : 유형별, 추정 및 동향 분석

• 맞춤형 암 백신 시장 : 유형 변동 분석
• 유형별
• 수지상 세포
• RNA 베이스(mRNA)
• 네오 안티겐베이스
• 종양 관련 항원(TAA) 백신
• 맞춤형 암 백신 시장 : 기술 변동 분석
• 기술별
• 세포 기반
• mRNA PCV
• 기타

제5장 맞춤형 암 백신 시장 : 유통 채널별, 추정 및 동향 분석

• 맞춤형 암 백신 시장 : 유통 변동 분석
• 유통 채널별
• 병원
• 클리닉
• 연구 및 학술기관

제6장 맞춤형 암 백신 시장 :지역별, 추정 및 동향 분석

• 맞춤형 암 백신 시장 점유율(지역별), 2024년 및 2030년
• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 시장 규모, 예측 동향 분석, 2018-2030년
• 북미
  • 북미의 맞춤형 암 백신 시장, 2018-2030년
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽의 맞춤형 암 백신 시장, 2018-2030년
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 아시아태평양의 맞춤형 암 백신 시장, 2018-2030년
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 라틴아메리카의 맞춤형 암 백신 시장, 2018-2030년
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 중동 및 아프리카의 맞춤형 암 백신 시장, 2018-2030년
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 주요 시장 진출기업에 의한 최근의 동향과 영향 분석
• 기업 분류
• 전략 매핑
• 기업의 시장 점유율 분석, 2024년
• 기업 프로파일
  • Dendreon Pharmaceuticals, LLC
  • Gritstone Bio
  • CureVac
  • NeoCura & Innovent
  • Stemirna Therapeutics
  • Elicio Therapeutics
  • Evaxion BIoTech
  • Imugene
  • Nouscom

>JHS

영문 목차

영문목차

Personalized Cancer Vaccine Market Growth & Trends:

The global personalized cancer vaccine market size is expected to reach USD 1.45 billion by 2030, registering a CAGR of 44.86% from 2025 to 2030, according to a new report by Grand View Research, Inc. The convergence of immunotherapy, genomics, and mRNA technologies drives the market growth. Unlike traditional vaccines, these personalized therapies are tailored to each patient's unique tumor profile, targeting neoantigens that arise from specific genetic mutations. This precision has opened new therapeutic horizons in oncology, especially for hard-to-treat cancers. The market growth is propelled by increasing investments in biotechnology, growing incidence of cancer worldwide, and advancements in next-generation sequencing. The rapid progression from clinical trials to regulatory designations, such as the European Medicines Agency's PRIME designation for Moderna and Merck's mRNA-4157/V940 in April 2023, is emblematic of this momentum. These vaccines are no longer speculative treatments; they are becoming integral to the future oncology landscape.

One of the most pivotal drivers of market growth is innovation in mRNA-based vaccine platforms. The success of COVID-19 mRNA vaccines accelerated public and private sector confidence in the modality, leading to increased funding and faster regulatory pathways. Moderna's investigational vaccine, mRNA-4157/V940, developed in partnership with Merck, exemplifies this progress. Granted PRIME designation by the EMA in April 2023, the vaccine showed promising results in Phase 2b trials (KEYNOTE-942), especially when paired with Merck's immunotherapy drug KEYTRUDA. Similarly, BioNTech, a pioneer in mRNA technology, showcased its oncology pipeline at the AACR Annual Meeting in April 2024, highlighting its mRNA-based cancer vaccines and antibody-drug conjugates. These innovations are allowing researchers to rapidly generate vaccine candidates based on tumor sequencing, personalize therapies in near real-time, and fine-tune immune responses to enhance efficacy, paving the way for a new era in cancer treatment.

Increased global awareness regarding HPV transmission, associated health risks, and the benefits of vaccination is a major factor driving market growth. Public health campaigns, social media outreach, and school-based education initiatives have played a pivotal role in changing perceptions and encouraging vaccine acceptance. In countries with robust healthcare communication strategies, such as Australia and the UK, HPV vaccine uptake is notably high, reflecting the impact of consistent, evidence-based awareness efforts. Gender-neutral vaccination messaging has also improved acceptance among male populations, particularly in response to the growing incidence of oropharyngeal and anal cancers in men. As stigma around sexual health diminishes and more people recognize the long-term cancer prevention benefits of vaccination, broader demographic groups are being reached. These awareness initiatives are not only increasing demand but are also leading to earlier vaccination, higher compliance rates, and more consistent market growth.

Regulatory incentives are playing a crucial role in accelerating the personalized cancer vaccine industry. Programs like the EMA's PRIME scheme or the FDA's Breakthrough Therapy designation are designed to expedite the development of promising therapies for serious conditions. Moderna and Merck's mRNA-4157/V940 vaccine receiving PRIME status is a testament to the regulators' commitment to fostering innovation in oncology. This designation was based on positive interim data suggesting that patients with high-risk stage III/IV melanoma had improved outcomes post-surgery when treated with the vaccine alongside KEYTRUDA. Similarly, BioNTech's participation in major scientific forums like AACR 2024, where it revealed significant clinical updates, underscores growing regulatory and scientific validation. These developments help boost investor confidence, shorten time-to-market for novel therapies, and offer hope for cancer patients who have limited treatment options, especially in the adjuvant setting.

Personalized Cancer Vaccine Market Report Highlights:

• Based on type, the dendritic cell segment accounted for the largest market share of 100% in 2024, driven by increasing demand for targeted and individualized immunotherapies.
• The cell-based technology segment led the market with a 100% revenue share in 2024, underpinned by its ability to harness the body's own immune system for targeted and adaptive anti-tumor responses. This segment includes therapies that utilize patient-derived cells, particularly dendritic cells, tumor-infiltrating lymphocytes (TILs), or engineered T-cells, to present tumor-specific antigens and stimulate a personalized immune attack against cancer cells.
• The hospitals segment dominated the market with a revenue share of 58.87% in 2024 and is expected to grow at the fastest CAGR over the forecast period, driven by several key factors. Hospitals serve as primary centers for cancer diagnosis, treatment, and follow-up care
• North America dominated the global market, with a share of 34.07% in 2024, driven by advancements in immunotherapy and a strong healthcare infrastructure. This growth is fueled by the increasing prevalence of cancer, with the U.S. alone reporting an estimated 1.9 million new cancer cases in 2022.
• The global personalized vaccine industry is led by several major companies, including Dendreon Pharmaceuticals, LLC, Gritstone Bio, CureVac, NeoCura & Innovent, Stemirna Therapeutics, Dendreon Pharmaceuticals, LLC, Elicio Therapeutics, Evaxion Biotech, Imugene, and Nouscom, all of which are strengthening their worldwide presence through strategies like launching new products, forging strategic partnerships, and expanding into new geographic regions.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Technology
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Distribution channel outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Personalized Cancer Vaccine Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Advances in genomic and immunotherapy technologies
  • 3.4.2. Rising cancer prevalence and demand for targeted treatments
  • 3.4.3. Collaborations and increased investment in cancer immunotherapy
• 3.5. Market Restraint Analysis
  • 3.5.1. High development and manufacturing costs
  • 3.5.2. Regulatory and logistical challenges
  • 3.5.3. Porter's Five Forces Analysis
  • 3.5.4. PESTEL Analysis

Chapter 4. Personalized Cancer Vaccine Market: Type Estimates & Trend Analysis

• 4.1. Personalized Cancer Vaccine Market: Type Movement Analysis
• 4.2. Personalized Cancer Vaccine Market Estimates and Forecast, by Type
• 4.3. Dendritic Cell
  • 4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.4. RNA-Based (mRNA)
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Neoantigen-Based
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Tumor-Associated Antigen (TAA) Vaccines
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Personalized Cancer Vaccine Market: Technology Movement Analysis
• 4.8. Personalized Cancer Vaccine Market Estimates and Forecast, by Technology
• 4.9. Cell-based
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. mRNA PCV
  • 4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Others
  • 4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Personalized Cancer Vaccine Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Personalized Cancer Vaccine Market: Distribution Movement Analysis
• 5.2. Personalized Cancer Vaccine Market Estimates and Forecast, by Distribution Channel
• 5.3. Hospitals
  • 5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.4. Clinics
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Research & Academic Institutes
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Personalized Cancer Vaccine Market: Regional Estimates & Trend Analysis

• 6.1. Personalized Cancer Vaccine Market Share By Region, 2024 & 2030
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Regional Market Dashboard
• 6.4. Global Regional Market Snapshot
• 6.5. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.6. North America
  • 6.6.1. North America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.6.2. U.S.
    • 6.6.2.1. Key Country Dynamics
    • 6.6.2.2. Competitive Scenario
    • 6.6.2.3. Regulatory Framework
    • 6.6.2.4. U.S. Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.6.3. Canada
    • 6.6.3.1. Key Country Dynamics
    • 6.6.3.2. Competitive Scenario
    • 6.6.3.3. Regulatory Framework
    • 6.6.3.4. Canada Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.6.4. Mexico
    • 6.6.4.1. Key Country Dynamics
    • 6.6.4.2. Competitive Scenario
    • 6.6.4.3. Regulatory Framework
    • 6.6.4.4. Mexico Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.7. Europe
  • 6.7.1. Europe Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.2. UK
    • 6.7.2.1. Key Country Dynamics
    • 6.7.2.2. Competitive Scenario
    • 6.7.2.3. Regulatory Framework
    • 6.7.2.4. UK Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.3. Germany
    • 6.7.3.1. Key Country Dynamics
    • 6.7.3.2. Competitive Scenario
    • 6.7.3.3. Regulatory Framework
    • 6.7.3.4. Germany Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.4. France
    • 6.7.4.1. Key Country Dynamics
    • 6.7.4.2. Competitive Scenario
    • 6.7.4.3. Regulatory Framework
    • 6.7.4.4. France Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.5. Italy
    • 6.7.5.1. Key Country Dynamics
    • 6.7.5.2. Competitive Scenario
    • 6.7.5.3. Regulatory Framework
    • 6.7.5.4. Italy Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.6. Spain
    • 6.7.6.1. Key Country Dynamics
    • 6.7.6.2. Competitive Scenario
    • 6.7.6.3. Regulatory Framework
    • 6.7.6.4. Spain Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.7. Denmark
    • 6.7.7.1. Key Country Dynamics
    • 6.7.7.2. Competitive Scenario
    • 6.7.7.3. Regulatory Framework
    • 6.7.7.4. Denmark Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.8. Sweden
    • 6.7.8.1. Key Country Dynamics
    • 6.7.8.2. Competitive Scenario
    • 6.7.8.3. Regulatory Framework
    • 6.7.8.4. Sweden Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.7.9. Norway
    • 6.7.9.1. Key Country Dynamics
    • 6.7.9.2. Competitive Scenario
    • 6.7.9.3. Regulatory Framework
    • 6.7.9.4. Norway Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.8. Asia Pacific
  • 6.8.1. Asia Pacific Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.2. Japan
    • 6.8.2.1. Key Country Dynamics
    • 6.8.2.2. Competitive Scenario
    • 6.8.2.3. Regulatory Framework
    • 6.8.2.4. Japan Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.3. China
    • 6.8.3.1. Key Country Dynamics
    • 6.8.3.2. Competitive Scenario
    • 6.8.3.3. Regulatory Framework
    • 6.8.3.4. China Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.4. India
    • 6.8.4.1. Key Country Dynamics
    • 6.8.4.2. Competitive Scenario
    • 6.8.4.3. Regulatory Framework
    • 6.8.4.4. India Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.5. Australia
    • 6.8.5.1. Key Country Dynamics
    • 6.8.5.2. Competitive Scenario
    • 6.8.5.3. Regulatory Framework
    • 6.8.5.4. Australia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.6. Thailand
    • 6.8.6.1. Key Country Dynamics
    • 6.8.6.2. Competitive Scenario
    • 6.8.6.3. Regulatory Framework
    • 6.8.6.4. Thailand Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.8.7. South Korea
    • 6.8.7.1. Key Country Dynamics
    • 6.8.7.2. Competitive Scenario
    • 6.8.7.3. Regulatory Framework
    • 6.8.7.4. South Korea Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.9. Latin America
  • 6.9.1. Latin America Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.9.2. Brazil
    • 6.9.2.1. Key Country Dynamics
    • 6.9.2.2. Competitive Scenario
    • 6.9.2.3. Regulatory Framework
    • 6.9.2.4. Brazil Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.9.3. Argentina
    • 6.9.3.1. Key Country Dynamics
    • 6.9.3.2. Competitive Scenario
    • 6.9.3.3. Regulatory Framework
    • 6.9.3.4. Argentina Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
• 6.10. MEA
  • 6.10.1. MEA Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.2. South Africa
    • 6.10.2.1. Key Country Dynamics
    • 6.10.2.2. Competitive Scenario
    • 6.10.2.3. Regulatory Framework
    • 6.10.2.4. South Africa Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.3. Saudi Arabia
    • 6.10.3.1. Key Country Dynamics
    • 6.10.3.2. Competitive Scenario
    • 6.10.3.3. Regulatory Framework
    • 6.10.3.4. Saudi Arabia Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.4. UAE
    • 6.10.4.1. Key Country Dynamics
    • 6.10.4.2. Competitive Scenario
    • 6.10.4.3. Regulatory Framework
    • 6.10.4.4. UAE Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)
  • 6.10.5. Kuwait
    • 6.10.5.1. Key Country Dynamics
    • 6.10.5.2. Competitive Scenario
    • 6.10.5.3. Regulatory Framework
    • 6.10.5.4. Kuwait Personalized Cancer Vaccine Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company Categorization
• 7.3. Strategy Mapping
• 7.4. Company Market Share Analysis, 2024
• 7.5. Company Profiles
  • 7.5.1. Dendreon Pharmaceuticals, LLC
    • 7.5.1.1. Overview
    • 7.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.1.3. Product Benchmarking
    • 7.5.1.4. Strategic Initiatives
  • 7.5.2. Gritstone Bio
    • 7.5.2.1. Overview
    • 7.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.2.3. Product Benchmarking
    • 7.5.2.4. Strategic Initiatives
  • 7.5.3. CureVac
    • 7.5.3.1. Overview
    • 7.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.3.3. Product Benchmarking
    • 7.5.3.4. Strategic Initiatives
  • 7.5.4. NeoCura & Innovent
    • 7.5.4.1. Overview
    • 7.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.4.3. Product Benchmarking
    • 7.5.4.4. Strategic Initiatives
  • 7.5.5. Stemirna Therapeutics
    • 7.5.5.1. Overview
    • 7.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.5.3. Product Benchmarking
    • 7.5.5.4. Strategic Initiatives
  • 7.5.6. Elicio Therapeutics
    • 7.5.6.1. Overview
    • 7.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.6.3. Product Benchmarking
    • 7.5.6.4. Strategic Initiatives
  • 7.5.7. Evaxion Biotech
    • 7.5.7.1. Overview
    • 7.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.7.3. Product Benchmarking
    • 7.5.7.4. Strategic Initiatives
  • 7.5.8. Imugene
    • 7.5.8.1. Overview
    • 7.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.8.3. Product Benchmarking
    • 7.5.8.4. Strategic Initiatives
  • 7.5.9. Nouscom
    • 7.5.9.1. Overview
    • 7.5.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 7.5.9.3. Product Benchmarking
    • 7.5.9.4. Strategic Initiatives

관련자료